Identification

Name
Amphotericin B
Accession Number
DB00681  (APRD00797)
Type
Small Molecule
Groups
Approved, Investigational
Description

Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.

Structure
Thumb
Synonyms
  • Amfotericina B
  • AMPH-b
  • Amphotericin B
  • Amphotéricine B
  • Amphotericinum B
  • C-AmB
  • Liposomal amphotericin b
External IDs
NSC-527017 / RP 17774
Product Ingredients
IngredientUNIICASInChI Key
Amphotericin B Cholesteryl Sulfate Complex774X4698X3120895-52-5Not applicable
CorifunginL26BTK479141610-51-9MTSXPVSZJVNPBE-ALEYTFIZSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbelcetSuspension5 mgIntravenousLeadiant Biosciences, Inc1997-09-25Not applicableCanada
AmBisomeInjection, powder, lyophilized, for solution50 mg/12.5mLIntravenousAstellas Pharma Inc1997-08-11Not applicableUs
AmBisomePowder, for solution50 mgIntravenousAstellas Pharma Inc2000-05-29Not applicableCanada
AmphotecInjection, lipid complex50 mg/50mgIntravenousKadmon Pharmaceuticals2005-05-202015-12-29Us
AmphotecInjection, lipid complex100 mg/100mgIntravenousKadmon Pharmaceuticals2005-05-202015-12-29Us
Amphotec 100 mgPowder, for suspension100 mgIntravenousThree Rivers Pharmaceuticals Llc2004-06-172013-08-22Canada
Amphotec 50 mgPowder, for suspension50 mgIntravenousThree Rivers Pharmaceuticals Llc2007-02-262013-08-22Canada
Amphotericin B for Injection, USPPowder, for solution50 mgIntravenousSterimax IncNot applicableNot applicableCanada
Fungizone Intravenous Injection 50mgPowder, for solution50 mgIntravenousBristol Myers Squibb1958-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amphotericin BInjection, powder, lyophilized, for solution50 mg/10mLIntravenousX Gen Pharmaceuticals, Inc.1992-04-29Not applicableUs
International/Other Brands
Abelect (Cephalon) / Ampho-Moronal (Dermapharm) / Amphocil (Alza) / Amphocin (Pfizer) / Amphotericin (Bristol-Myers Squibb) / Fungilin (Sigma) / Fungisome / Fungizone (Bristol-Myers Squibb) / Fungizone Intravenous (Bristol-Myers Squibb) / Halizon (Fuji Yakuhin)
Categories
UNII
7XU7A7DROE
CAS number
1397-89-3
Weight
Average: 924.079
Monoisotopic: 923.487849915
Chemical Formula
C47H73NO17
InChI Key
APKFDSVGJQXUKY-INPOYWNPSA-N
InChI
InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1
IUPAC Name
(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-{[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid
SMILES

Pharmacology

Indication

Used to treat potentially life threatening fungal infections.

Structured Indications
Pharmacodynamics

Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.

Mechanism of action

Amphotericin B is fungistatic or fungicidal depending on the concentration obtained in body fluids and the susceptibility of the fungus. The drug acts by binding to sterols (ergosterol) in the cell membrane of susceptible fungi. This creates a transmembrane channel, and the resultant change in membrane permeability allowing leakage of intracellular components. Ergosterol, the principal sterol in the fungal cytoplasmic membrane, is the target site of action of amphotericin B and the azoles. Amphotericin B, a polyene, binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death.

TargetActionsOrganism
AErgosterol
binder
Candida albicans
Absorption

Bioavailability is 100% for intravenous infusion.

Volume of distribution
Not Available
Protein binding

Highly bound (>90%) to plasma proteins.

Metabolism

Exclusively renal

Route of elimination
Not Available
Half life

An elimination half-life of approximately 15 days follows an initial plasma half-life of about 24 hours.

Clearance
  • 39 +/- 22 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 1 mg/kg/day at Day 1]
  • 17 +/- 6 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 1 mg/kg/day 3-20 days later]
  • 51 +/- 44 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 2.5 mg/kg/day at Day 1]
  • 22 +/- 15 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 2.5 mg/kg/day 3-20 days later]
  • 21 +/- 14 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 5 mg/kg/day at Day 1]
  • 11 +/- 6 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 5 mg/kg/day 3-20 days later]
Toxicity

Oral, rat: LD50 = >5 gm/kg. Amphotericin B overdoses can result in cardio-respiratory arrest.

Affected organisms
  • Various Fungus Species
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Amphotericin B.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Amphotericin B.Experimental, Illicit
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with 2-mercaptobenzothiazole.Vet Approved
5-androstenedione5-androstenedione may increase the hypokalemic activities of Amphotericin B.Experimental, Illicit
AcebutololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Acebutolol.Approved
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigoxin.Experimental
AclarubicinAmphotericin B may increase the nephrotoxic activities of Aclarubicin.Investigational
AlclometasoneAlclometasone may increase the hypokalemic activities of Amphotericin B.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Aldesleukin.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Amphotericin B.Experimental, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Aliskiren.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Amphotericin B.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Amphotericin B.Approved, Investigational
AmikacinAmphotericin B may increase the nephrotoxic activities of Amikacin.Approved, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Amphotericin B.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Amphotericin B.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Amorolfine.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Amrinone.Approved
AmrubicinAmphotericin B may increase the nephrotoxic activities of Amrubicin.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Amyl Nitrite.Approved
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Amphotericin B.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Amphotericin B.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Amphotericin B.Investigational
AnidulafunginThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Anidulafungin.Approved, Investigational
annamycinAmphotericin B may increase the nephrotoxic activities of annamycin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Apraclonidine.Approved
ApramycinAmphotericin B may increase the nephrotoxic activities of Apramycin.Experimental, Vet Approved
ArbekacinAmphotericin B may increase the nephrotoxic activities of Arbekacin.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Amphotericin B.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Arotinolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Artemether.Approved
AtamestaneAtamestane may increase the hypokalemic activities of Amphotericin B.Investigational
AtenololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Atenolol.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Azilsartan medoxomil.Approved
AzimilideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Azimilide.Investigational
Bafilomycin A1The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Bafilomycin A1.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Amphotericin B.Experimental
BarbitalBarbital may increase the hypotensive activities of Amphotericin B.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Barnidipine.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Amphotericin B.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
BekanamycinAmphotericin B may increase the nephrotoxic activities of Bekanamycin.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Benazepril.Approved, Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bencyclane.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bendroflumethiazide.Approved
BenidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Benidipine.Approved, Investigational
Benzoic AcidThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Benzoic Acid.Approved
BepridilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Betaxolol.Approved
BifonazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Bifonazole.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bortezomib.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Brefeldin A.Experimental
BretyliumThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Brimonidine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bromocriptine.Approved, Investigational
BudesonideBudesonide may increase the hypokalemic activities of Amphotericin B.Approved
BumetanideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bupivacaine.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Amphotericin B.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Amphotericin B.Approved, Investigational
ButenafineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Butenafine.Approved
ButoconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Butoconazole.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Candesartan cilexetil.Approved
CandicidinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Candicidin.Withdrawn
Capric acidThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Capric acid.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Carbetocin.Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Caroverine.Experimental
CarteololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Carvedilol.Approved, Investigational
CaspofunginThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Caspofungin.Approved
CeruleninThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Cerulenin.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Chloroxine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Chlorthalidone.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
CiclopiroxThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Ciclopirox.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Amphotericin B.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Amphotericin B.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Amphotericin B.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Amphotericin B.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Amphotericin B.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clonidine.Approved
ClotrimazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clozapine.Approved
ColistimethateAmphotericin B may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Amphotericin B.Approved, Investigational
CordycepinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Cordycepin.Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Amphotericin B.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Amphotericin B.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Amphotericin B.Approved
CyclosporineAmphotericin B may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Cymarin.Experimental
DapagliflozinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Dapagliflozin.Approved
DarodipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Darodipine.Experimental
DaunorubicinAmphotericin B may increase the nephrotoxic activities of Daunorubicin.Approved
DeflazacortDeflazacort may increase the hypokalemic activities of Amphotericin B.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Desflurane.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside.Approved
DesonideDesonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Amphotericin B.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Amphotericin B.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Amphotericin B.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Amphotericin B.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Dexmedetomidine.Approved, Vet Approved
DibekacinAmphotericin B may increase the nephrotoxic activities of Dibekacin.Experimental
DichloropheneThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Dichlorophene.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Diclofenamide.Approved
DidanosineDidanosine can cause a decrease in the absorption of Amphotericin B resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Amphotericin B.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
DifluprednateDifluprednate may increase the hypokalemic activities of Amphotericin B.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin Immune Fab (Ovine).Approved
DihydrostreptomycinAmphotericin B may increase the nephrotoxic activities of Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Dipyridamole.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Amphotericin B.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Amphotericin B.Approved
DotarizineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Dotarizine.Investigational
DoxazosinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Doxazosin.Approved
DoxorubicinAmphotericin B may increase the nephrotoxic activities of Doxorubicin.Approved, Investigational
DuloxetineAmphotericin B may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Econazole.Approved
EfinaconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Efinaconazole.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Enalaprilat.Approved
EperisoneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Eperisone.Approved, Investigational
EpirubicinAmphotericin B may increase the nephrotoxic activities of Epirubicin.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Amphotericin B.Experimental
EquilinEquilin may increase the hypokalemic activities of Amphotericin B.Approved
EsmololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Esmolol.Approved
EstroneEstrone may increase the hypokalemic activities of Amphotericin B.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Amphotericin B.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Etacrynic acid.Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Amphotericin B.Approved
FelodipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fendiline.Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fenoldopam.Approved
FenticonazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Fenticonazole.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fimasartan.Approved, Investigational
fluasteronefluasterone may increase the hypokalemic activities of Amphotericin B.Investigational
FluconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Flucytosine.Approved
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Amphotericin B.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Flunarizine.Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Amphotericin B.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Amphotericin B.Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Amphotericin B.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Amphotericin B.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Amphotericin B.Approved
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Amphotericin B.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Amphotericin B.Approved
FlutrimazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Flutrimazole.Experimental
FormestaneFormestane may increase the hypokalemic activities of Amphotericin B.Approved, Investigational, Withdrawn
FoscarnetFoscarnet may increase the nephrotoxic activities of Amphotericin B.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Amphotericin B can be decreased when it is combined with Fosphenytoin.Approved
FramycetinAmphotericin B may increase the nephrotoxic activities of Framycetin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Gallopamil.Investigational
GeneticinAmphotericin B may increase the nephrotoxic activities of Geneticin.Experimental
GentamicinAmphotericin B may increase the nephrotoxic activities of Gentamicin.Approved, Vet Approved
GENTAMICIN C1AAmphotericin B may increase the nephrotoxic activities of GENTAMICIN C1A.Experimental
GitoformateThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Gitoformate.Experimental
GlyphosateThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Glyphosate.Experimental
GPX-150Amphotericin B may increase the nephrotoxic activities of GPX-150.Investigational
GriseofulvinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Griseofulvin.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Guanfacine.Approved, Investigational
HachimycinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Hachimycin.Experimental
HalcinonideHalcinonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational, Withdrawn
HaloproginThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Haloprogin.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Amphotericin B.Investigational
HexetidineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Hexetidine.Approved, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Amphotericin B.Approved
HydralazineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Hydroflumethiazide.Approved, Investigational
Hygromycin BAmphotericin B may increase the nephrotoxic activities of Hygromycin B.Vet Approved
IdarubicinAmphotericin B may increase the nephrotoxic activities of Idarubicin.Approved
IloprostThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Indapamide.Approved
IndoraminThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Indoramin.Withdrawn
INNO-206Amphotericin B may increase the nephrotoxic activities of INNO-206.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Irbesartan.Approved, Investigational
IsepamicinAmphotericin B may increase the nephrotoxic activities of Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isocarboxazid.Approved
IsoconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Isoconazole.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isradipine.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Amphotericin B.Investigational
ItraconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Itraconazole.Approved, Investigational
KanamycinAmphotericin B may increase the nephrotoxic activities of Kanamycin.Approved, Investigational, Vet Approved
KetoconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lamotrigine.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lanatoside C.Experimental
LercanidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Levobupivacaine.Approved, Investigational
LevodopaAmphotericin B may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Levosimendan.Approved, Investigational
LidoflazineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lidoflazine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lisinopril.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lofexidine.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Amphotericin B.Approved
LoteprednolLoteprednol may increase the hypokalemic activities of Amphotericin B.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Mannitol.Approved, Investigational
ME-609ME-609 may increase the hypokalemic activities of Amphotericin B.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Mecamylamine.Approved
MedrysoneMedrysone may increase the hypokalemic activities of Amphotericin B.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Amphotericin B.Vet Approved
MepartricinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Mepartricin.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Amphotericin B.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Amphotericin B.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Metoprolol.Approved, Investigational
MetrizamideAmphotericin B may increase the nephrotoxic activities of Metrizamide.Approved
MevastatinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Mevastatin.Experimental
MibefradilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Mibefradil.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Micafungin.Approved, Investigational
MiconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Miconazole.Approved, Investigational, Vet Approved
MicronomicinAmphotericin B may increase the nephrotoxic activities of Micronomicin.Experimental
MiltefosineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Miltefosine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Minoxidil.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Moexipril.Approved
MometasoneMometasone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
MonensinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Monensin.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Moxonidine.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Myxothiazol.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nadolol.Approved
NaftifineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Naftifine.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Naftopidil.Investigational
NatamycinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Natamycin.Approved
NCX 1022NCX 1022 may increase the hypokalemic activities of Amphotericin B.Investigational
NeamineAmphotericin B may increase the nephrotoxic activities of Neamine.Experimental
NebivololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nebivolol.Approved, Investigational
NeomycinAmphotericin B may increase the nephrotoxic activities of Neomycin.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nesiritide.Approved, Investigational
NetilmicinAmphotericin B may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Amphotericin B.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nifedipine.Approved
NifuratelThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Nifuratel.Experimental
NiguldipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Niguldipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Nikkomycin Z.Investigational
NiludipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitroprusside.Approved
NitroxolineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Nitroxoline.Approved
NystatinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Nystatin.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Obinutuzumab.Approved
OleandrinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Amphotericin B.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Olmesartan.Approved, Investigational
OmoconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Omoconazole.Experimental
OtiloniumThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Otilonium.Experimental, Investigational
OuabainThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ouabain.Approved
OxiconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Oxiconazole.Approved
OxprenololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with pafuramidine.Investigational
PapaverineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Amphotericin B.Approved
ParomomycinAmphotericin B may increase the nephrotoxic activities of Paromomycin.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Penbutolol.Approved, Investigational
PentamidineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Pentamidine.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Amphotericin B.Approved, Vet Approved
PerhexilineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Perhexiline.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Peruvoside.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Amphotericin B.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Amphotericin B.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amphotericin B.Approved
PimozideAmphotericin B may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pinaverium.Approved
PindololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pipamperone.Approved, Investigational
PirarubicinAmphotericin B may increase the nephrotoxic activities of Pirarubicin.Investigational
PlazomicinAmphotericin B may increase the nephrotoxic activities of Plazomicin.Investigational
PlicamycinAmphotericin B may increase the nephrotoxic activities of Plicamycin.Approved, Investigational, Withdrawn
PosaconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pramipexole.Approved, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Amphotericin B.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Amphotericin B.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Prazosin.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Amphotericin B.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pregabalin.Approved, Illicit, Investigational
PregnenolonePregnenolone may increase the hypokalemic activities of Amphotericin B.Experimental, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Prenylamine.Withdrawn
PrimidonePrimidone may increase the hypotensive activities of Amphotericin B.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Amphotericin B.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Propranolol.Approved, Investigational
ProscillaridinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Proscillaridin.Experimental
PuromycinAmphotericin B may increase the nephrotoxic activities of Puromycin.Experimental
PyrrolnitrinThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Pyrrolnitrin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Amphotericin B.Approved
RadicicolThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Radicicol.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ramipril.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Amphotericin B.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Reserpine.Approved, Investigational
RibostamycinAmphotericin B may increase the nephrotoxic activities of Ribostamycin.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Amphotericin B.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Amphotericin B.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Amphotericin B.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Amphotericin B.Approved, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Amphotericin B.Approved
RiociguatThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Riociguat.Approved
RisedronateThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Risedronate.Approved, Investigational
RisperidoneAmphotericin B may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Rotigotine.Approved
SabarubicinAmphotericin B may increase the nephrotoxic activities of Sabarubicin.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sacubitril.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Salicylhydroxamic Acid.Experimental
Salicylic acidThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Amphotericin B.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Selegiline.Approved, Investigational, Vet Approved
SertaconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Sertaconazole.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sevoflurane.Approved, Vet Approved
SinefunginThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Sinefungin.Experimental
SirolimusThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Sirolimus.Approved, Investigational
SisomicinAmphotericin B may increase the nephrotoxic activities of Sisomicin.Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sodium Nitrite.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Amphotericin B.Approved
SotalolThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sotalol.Approved
SP1049CAmphotericin B may increase the nephrotoxic activities of SP1049C.Investigational
SpectinomycinAmphotericin B may increase the nephrotoxic activities of Spectinomycin.Approved, Investigational, Vet Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Streptokinase.Approved, Investigational
StreptomycinAmphotericin B may increase the nephrotoxic activities of Streptomycin.Approved, Vet Approved
StreptozocinAmphotericin B may increase the nephrotoxic activities of Streptozocin.Approved
SucralfateSucralfate can cause a decrease in the absorption of Amphotericin B resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SufentanilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sufentanil.Approved, Investigational
SulconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Sulconazole.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Amphotericin B.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Amphotericin B.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tamsulosin.Approved, Investigational
TavaboroleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Tavaborole.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Telmisartan.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Terazosin.Approved
TerbinafineThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Terconazole.Approved
TerodilineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Terodiline.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Amphotericin B.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Amphotericin B.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Thioridazine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Thymol.Approved
TimololThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Timolol.Approved
TioconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Tioconazole.Approved
TixocortolTixocortol may increase the hypokalemic activities of Amphotericin B.Approved
TizanidineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tizanidine.Approved
TobramycinAmphotericin B may increase the nephrotoxic activities of Tobramycin.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tolcapone.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Tolciclate.Experimental
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tolfenamic Acid.Approved
TolnaftateThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Tolnaftate.Approved, Vet Approved
TorasemideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Amphotericin B.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Triamterene.Approved
TrimetrexateThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Trimetrexate.Approved, Investigational
UlobetasolUlobetasol may increase the hypokalemic activities of Amphotericin B.Approved
ValrubicinAmphotericin B may increase the nephrotoxic activities of Valrubicin.Approved
ValsartanThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Valsartan.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Vinpocetine.Investigational
VoriconazoleThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Voriconazole.Approved, Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Amphotericin B.Approved
Zoptarelin doxorubicinAmphotericin B may increase the nephrotoxic activities of Zoptarelin doxorubicin.Investigational
ZorubicinAmphotericin B may increase the nephrotoxic activities of Zorubicin.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Frank Sipos, "Process for producing the methyl ester of amphotericin B." U.S. Patent US4035567, issued March, 1976.

US4035567
General References
Not Available
External Links
Human Metabolome Database
HMDB14819
KEGG Drug
D00203
KEGG Compound
C06573
PubChem Compound
5280965
PubChem Substance
46505473
ChemSpider
10237579
ChEBI
2682
ChEMBL
CHEMBL267345
Therapeutic Targets Database
DAP001322
PharmGKB
PA448415
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Amphotericin_B
ATC Codes
J02AA01 — Amphotericin bA07AA07 — Amphotericin bA01AB04 — Amphotericin bG01AA03 — Amphotericin b
AHFS Codes
  • 08:14.28 — Polyenes
FDA label
Download (1.02 MB)
MSDS
Download (73.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableInfection NOS1
1CompletedNot AvailableNormal Healthy Subjects1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Meningitis, Cryptococcal1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Meningitis, Cryptococcal1
1, 2WithdrawnTreatmentEffects of Immunotherapy / Leishmaniasis1
2Active Not RecruitingTreatmentAspergillosis, Allergic Bronchopulmonary1
2CompletedPreventionAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome1
2CompletedPreventionFungus Diseases1
2CompletedTreatmentAspergillosis1
2CompletedTreatmentFevers / Neutropenias1
2CompletedTreatmentFungus Diseases / Hematopoietic Stem Cell Transplantation (HSCT)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Meningitis, Cryptococcal2
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Oral Candidiasis1
2CompletedTreatmentInvasive Pulmonary Aspergillosis / Leukaemia, Lymphoblastic / Myeloblastic Leukemia1
2CompletedTreatmentMeningitis, Cryptococcal1
2CompletedTreatmentMucormycosis1
2CompletedTreatmentPrimary Visceral Leishmaniasis1
2CompletedTreatmentVisceral Leishmaniasis1
2CompletedTreatmentZygomycosis1
2Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Meningitis / Meningitis streptococcal / Meningoencephalitis1
2RecruitingTreatmentChronic Mucocutaneous Candidiasis (CMC)1
2SuspendedPreventionLung Transplant Recipients1
2TerminatedTreatmentAspergillosis1
2TerminatedTreatmentMeningitis, Cryptococcal1
2TerminatedTreatmentVisceral Leishmaniasis1
2Unknown StatusPreventionLeukemia Acute Myeloid Leukemia (AML)1
3Active Not RecruitingTreatmentVisceral Leishmaniasis1
3CompletedPreventionInfections, Fungal / Transplantation, Lung2
3CompletedPreventionInvasive Fungal Disease1
3CompletedPreventionMycoses / Transplantation, Liver1
3CompletedSupportive CareCancers2
3CompletedSupportive CareInfection NOS1
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Aspergillosis / Human Immunodeficiency Virus (HIV) Infections / Immunologic Deficiency Syndromes / Neutropenias1
3CompletedTreatmentBlastomycosis / Histoplasmosis / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentChronic Rhinosinusitis1
3CompletedTreatmentDisseminated Leishmaniasis1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Meningitis, Cryptococcal1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Mycoses1
3CompletedTreatmentInvasive Aspergillosis / Other Fungal Infections1
3CompletedTreatmentInvasive Fungal Infections / Malignancies, Hematologic1
3CompletedTreatmentVisceral Leishmaniasis6
3CompletedTreatmentCandidiasis infection1
3TerminatedDiagnosticAspergillosis1
3TerminatedTreatmentChronic Lung Diseases / Transplantation, Lung1
3TerminatedTreatmentCandidiasis infection1
3Unknown StatusPreventionPediatric Acute Leukemia Induction1
3Unknown StatusTreatmentBacterial Vaginosis (BV) / Candidiasis infection1
4CompletedPreventionLeukemias1
4CompletedPreventionCandidiasis infection1
4CompletedTreatmentCandidemia / Candidiasis, Invasive1
4CompletedTreatmentCentral Line Fungal Infections1
4CompletedTreatmentInfections, Fungal / Liver Diseases1
4CompletedTreatmentInvasive Aspergillosis1
4CompletedTreatmentPost-kala-azar Dermal Leishmaniasis1
4CompletedTreatmentVisceral Leishmaniasis1
4Not Yet RecruitingOtherObesity, Morbid1
4Not Yet RecruitingTreatmentMeningitis, Cryptococcal1
4Not Yet RecruitingTreatmentVisceral Leishmaniasis1
4RecruitingTreatmentBlastomycosis1
4TerminatedPreventionInfections, Fungal1
4TerminatedPreventionTransplantation, Liver1
4TerminatedTreatmentDuration of Neutropenia Following Chemotherapy > 10 Days / Malignant Hemopathies1
4TerminatedTreatmentNeutropenia, Febrile1
4TerminatedTreatmentVisceral Leishmaniasis1
4Unknown StatusPreventionInvasive Pulmonary Aspergillosis1
4Unknown StatusPreventionProphylaxis of Candida Infections / Sepsis1
Not AvailableActive Not RecruitingNot AvailableSystemic Fungal Infections1
Not AvailableCompletedTreatmentEsophageal Candidiasis / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Meningitis, Cryptococcal7
Not AvailableUnknown StatusTreatmentMeningitis, Cryptococcal1

Pharmacoeconomics

Manufacturers
  • Apothecon inc div bristol myers squibb
  • Sigma tau pharmaceuticals inc
  • Three rivers pharmaceuticals llc
  • Astellas pharma us inc
  • Abbott laboratories
  • Abraxis pharmaceutical products
  • Teva parenteral medicines inc
  • X gen pharmaceuticals inc
  • Bristol myers squibb co
Packagers
Dosage forms
FormRouteStrength
SuspensionIntravenous5 mg
Injection, powder, lyophilized, for solutionIntravenous50 mg/12.5mL
Powder, for solutionIntravenous50 mg
Injection, lipid complexIntravenous100 mg/100mg
Injection, lipid complexIntravenous50 mg/50mg
Powder, for suspensionIntravenous100 mg
Powder, for suspensionIntravenous50 mg
Injection, powder, lyophilized, for solutionIntravenous50 mg/10mL
Prices
Unit descriptionCostUnit
Ambisome 50 mg vial188.4USD vial
Amphotec 100 mg vial160.0USD vial
Amphotec 50 mg vial93.33USD vial
Fungizone Iv 50 mg/vial72.5USD vial
Amphotericin b powder29.99USD g
Amphotericin b 50 mg vial24.5USD vial
Abelcet 5 mg/ml vial p-f12.0USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1339008No1997-03-252014-03-25Canada
CA1336890No1995-09-052012-09-05Canada
US6406713No1999-06-182019-06-18Us
US5874104No1996-02-232016-02-23Us
US5965156No1996-10-122016-10-12Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)170.0 °CNot Available
water solubility750 mg/L (at 28 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0819 mg/mLALOGPS
logP-0.66ALOGPS
logP-2.3ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.58ChemAxon
pKa (Strongest Basic)9.11ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count12ChemAxon
Polar Surface Area319.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity244.67 m3·mol-1ChemAxon
Polarizability99.45 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9308
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7539
P-glycoprotein substrateSubstrate0.6404
P-glycoprotein inhibitor INon-inhibitor0.7322
P-glycoprotein inhibitor IINon-inhibitor0.5977
Renal organic cation transporterNon-inhibitor0.9491
CYP450 2C9 substrateNon-substrate0.7992
CYP450 2D6 substrateNon-substrate0.8785
CYP450 3A4 substrateSubstrate0.5496
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.941
CYP450 2D6 inhibitorNon-inhibitor0.9444
CYP450 2C19 inhibitorNon-inhibitor0.921
CYP450 3A4 inhibitorNon-inhibitor0.9381
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.984
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9682
BiodegradationNot ready biodegradable0.9414
Rat acute toxicity2.2357 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9777
hERG inhibition (predictor II)Non-inhibitor0.7887
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues / Hexoses / O-glycosyl compounds / Beta hydroxy acids and derivatives / Oxanes / Dicarboxylic acids and derivatives / Secondary alcohols / 1,2-aminoalcohols / Amino acids / Lactones
show 11 more
Substituents
Aminoglycoside core / Macrolide / Hexose monosaccharide / O-glycosyl compound / Glycosyl compound / Beta-hydroxy acid / Dicarboxylic acid or derivatives / Oxane / Hydroxy acid / Monosaccharide
show 24 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
antibiotic antifungal drug, macrolide antibiotic, polyene antibiotic (CHEBI:2682) / Plyenes (C06573) / Polyenes (LMPK06000002)

Targets

1. Ergosterol
Kind
Small molecule
Organism
Candida albicans
Pharmacological action
Yes
Actions
Binder
References
  1. Laniado-Laborin R, Cabrales-Vargas MN: Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009 Dec 31;26(4):223-7. doi: 10.1016/j.riam.2009.06.003. [PubMed:19836985]
  2. Baginski M, Czub J: Amphotericin B and its new derivatives - mode of action. Curr Drug Metab. 2009 Jun;10(5):459-69. [PubMed:19689243]
  3. Baginski M, Sternal K, Czub J, Borowski E: Molecular modelling of membrane activity of amphotericin B, a polyene macrolide antifungal antibiotic. Acta Biochim Pol. 2005;52(3):655-8. Epub 2005 Aug 5. [PubMed:16086075]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18